NCT00520000View on ClinicalTrials.gov

Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Metastatic Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

May 31, 2006

Study Completion Date

September 30, 2007

Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG

Carboplatin

standard dose of area under the curve (AUC) AUC of 6 in all arms

DRUG

Abraxane

75mg/m2 - 150 mg/m2 given on days 1, 8, 15 of every 28 day cycle

DRUG

Abraxane

180mg/m2 - 340mg/m2, repeated every 21 days

DRUG

Abraxane

100mg/m2 - 175/mg/m2 given on days 1, 8 of every 21 day cycle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

UNC Lineberger Comprehensive Cancer Center

OTHER

NCT00520000 - Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter